Immunic. has been granted a patent for a white crystalline polymorph A of the calcium salt of a specific compound, characterized by distinct X-ray diffraction patterns. This polymorph is noted for its ability to inhibit dihydroorotate dehydrogenase (DHODH) and is intended for use in treating related diseases. GlobalData’s report on Immunic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Immunic, Wearable breast pumps was a key innovation area identified from patents. Immunic's grant share as of July 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline polymorph a of calcium salt compound
The granted patent US12037305B2 describes a novel crystalline polymorph A of a hydrate of the calcium salt of a specific compound, referred to as formula I. The claims detail the unique characteristics of this polymorph, including its distinct X-ray diffraction patterns, FT Raman and IR absorption spectra, and 1H-NMR spectral data. Additionally, the patent outlines a pharmaceutical formulation that incorporates this polymorph along with a pharmaceutically acceptable excipient, emphasizing that the polymorph A should have a tetrahydrofuran (THF) content of less than 720 ppm. The polymorph is proposed for use in treating various diseases, including graft versus host reactions, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Furthermore, the patent provides a comprehensive process for manufacturing crystalline polymorph A. This process involves several steps, including the preparation of a suspension from calcium hydroxide and a free acid form of the compound, followed by a series of washing, slurring, and recovery steps using various organic solvents. The claims also specify conditions such as temperature ranges for slurring and the use of specific organic solvents like DMF, DMSO, and THF. Additional steps for drying, milling, and recrystallization may be included to enhance the quality of the final product. The patent thus presents a detailed methodology for producing a crystalline polymorph A with a defined molar ratio of the compound, calcium, and water, contributing to the field of pharmaceutical formulations.
To know more about GlobalData’s detailed insights on Immunic, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
